VSIR and non-small cell lung carcinoma: In addition, CA-170, an oral small-molecule inhibitor of VISTA and PD-L1, achieved a 75% clinical benefit rate (CBR) and prolonged progression-free survival (PFS) in non-squamous NSCLC patients during a phase II trial [303]​.